Anupam Rasayan Launches Open Offer for Bliss GVS Pharma Stake

Anupam Rasayan India Limited will acquire up to 26.00% of Bliss GVS Pharma Limited's equity capital at ₹299.00 per share.

Reader Takeaway: Ownership change creates exit opportunity; new promoter aims for growth. Potential regulatory hurdles remain.

What just happened

Anupam Rasayan India Limited has announced a mandatory open offer to acquire up to 26.00% stake in Bliss GVS Pharma Limited. The offer price is set at ₹299.00 per share, with the tendering period scheduled from July 16, 2026, to July 29, 2026. This acquisition follows Anupam Rasayan's agreement to purchase 43.30% of Bliss GVS Pharma's shares from existing promoters.

Why this matters

This transaction signals a significant shift in control for Bliss GVS Pharma. Upon successful completion, Anupam Rasayan will become the new promoter, while the current promoters will be reclassified as public shareholders. The open offer provides existing shareholders of Bliss GVS Pharma an exit opportunity at a premium.

The backstory

Bliss GVS Pharma reported total revenue of ₹1,000.64 crore and a net income of ₹134.73 crore for FY 2026, with basic EPS of ₹12.23. In the same period, Anupam Rasayan India had total revenue of ₹2,383.63 crore and a net income of ₹222.20 crore, with basic EPS of ₹15.09.

What changes now

Anupam Rasayan intends to support Bliss GVS Pharma's management in continuing its growth trajectory. The change in promoter status is a direct consequence of the share purchase agreement and will be executed in compliance with SEBI regulations.

Risks to watch

The open offer is not conditional on a minimum acceptance level. However, the acquisition is subject to necessary statutory and governmental approvals, which investors should closely monitor. The financial arrangements made by Anupam Rasayan appear robust, including ₹394 crore in cash, ₹644 crore in bank limits, and a ₹2,000 crore non-binding letter for acquisition financing.

Peer comparison

In FY 2026, Bliss GVS Pharma reported revenues of ₹1,000.64 crore and a net profit of ₹134.73 crore. Anupam Rasayan India, the acquirer, posted higher revenues of ₹2,383.63 crore and a net profit of ₹222.20 crore for the same fiscal year.

Context metrics (time-bound)

• Offer Period: July 16, 2026 - July 29, 2026
• Offer Price: ₹299.00 per share
• Stake Acquired: Up to 26.00%
• Promoter Stake Post-SPA: 43.30% (to be acquired)
• Bliss GVS Pharma FY26 Revenue: ₹1,000.64 crore
• Bliss GVS Pharma FY26 Net Income: ₹134.73 crore

What to track next

Investors should pay close attention to the participation level in the open offer and the finalization of all required regulatory approvals. The successful integration and future performance of Bliss GVS Pharma under new management will be key.